Table 2:

Treatment used at scanning for each study groupa

MedicationCSSC (No.)Software-Assisted (No.)
Fingolimod35.85% (19)37.30% (282)
Natalizumab32.08% (17)27.12% (205)
Dimethyl fumarate3.77% (2)7.80% (59)
Alemtuzumab1.89% (1)3.44% (26)
Glatiramer acetate5.66% (3)2.78% (21)
Interferon β5.66% (3)3.57% (27)
Otherb9.43% (5)6.61% (50)
No active treatment5.66% (3)11.38% (86)
Total100% (53)100% (756)
Proportion on higher efficacy therapies (fingolimod/natalizumab/alemtuzumab)69.87%67.84%

  • ↵a This table summarizes the number and proportion for each disease-modifying agent at scanning.

  • ↵b Other treatments include teriflunomide, ocrelizumab, rituximab, stem cell transplantation.